Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Proteomics International, inVentiv Health Sign Biosimilar Agreement

Published: Saturday, March 01, 2014
Last Updated: Wednesday, March 12, 2014
Bookmark and Share
Partnership offers developers full service biosimilar expertise on a global scale.

Proteomics International has signed a collaborative agreement with inVentiv Health Clinical. 

Biosimilar and biologic development begins with extensive structural and functional characterization. Proteomics International provides structural characterization and QC testing of proposed and referenced products with an advanced suite of scientific instrumentation. These services complement inVentiv Health’s array of bioanalytical capabilities from clinical development through commercialization in support of biosimilar development. 

The Proteomics International agreement with inVentiv Clinical offers developers the ability to seamlessly transition from characterization to clinical trials thereby streamlining the process and providing a competitive advantage in the race to market. 

“We welcome the partnership with inVentiv as it represents a significant opportunity for us in furthering expansion into bio-generic markets,” said Dr. Richard Lipscombe, Managing Director of Proteomics International. “This collaboration will position both companies to better assist biosimilar and biologics developers in this emerging field and ever-changing regulatory environment.” 

“The strengths of Proteomic International to demonstrate biosimilarity combined with inVentiv biologic clinical, commercial and consulting expertise is a winning solution for clients,” said Dr. George Scott, Vice President, Bioanalytical Services for inVentiv Clinical. “Together we offer the full breadth and scope of an integrated roadmap of biosimilar development services to help navigate the complex regulatory and development landscape from early strategic planning, clinical trial conduct, and registration to commercialization.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Coding and Computers Help Spot Methane, Explosives
Coded apertures improve and shrink mass spectrometers for field use.
Why Bearcats Smell Like Buttered Popcorn
Researchers pinpoint chemical compound that gives rare animal its popcorn-like scent.
UCSD Scientists Receive NIH Grant to Combat Antibiotic Resistance
Interdisciplinary program will use systems biology approaches to understand how antibiotics work in concert with patient’s immune system.
Virus Causing Tilapia Die-Offs Identified
Discovery of the virus causing Tilapia die-offs in Israel and Ecuador points the way to protecting a fish that feeds multitudes.
Novel Collagen Fingerprinting Identifies A Neanderthal
Study from the universities of Oxford and Manchester uses ZooMS technique to identify traces of an extinct human.
Hope for Combating Muscular Dystrophy
Decoding a sugar molecule and identifying a mechanism linking it to MS could help in the development of therapy for the disease.
Decoding Sugar Molecules Offers New Key For Combating Muscular Dystrophy
Japanese scientists find a rare sugar unit called ribitol 5-phosphate within the sugar molecules on the surface of muscle cells. Mutations in 3 genes linked to muscular dystrophy affect the creation of this sugar molecule.
A Vision for Precision Medicine
The University of Manchester and the University of Dundee partner to share disease screening data.
New Targets for Diabetes, Inflammation Discovered
The Scripps Research Institute and Salk Scientists discover 'outlier' enzymes that could offer new targets to treat diabetes and inflammation.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!